<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5940">
  <stage>Registered</stage>
  <submitdate>7/12/2015</submitdate>
  <approvaldate>7/12/2015</approvaldate>
  <nctid>NCT02632760</nctid>
  <trial_identification>
    <studytitle>Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery</studytitle>
    <scientifictitle>Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery</scientifictitle>
    <utrn />
    <trialacronym>ITACS</trialacronym>
    <secondaryid>605/15</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ferric carboxymaltose
Treatment: drugs - Placebo

Active Comparator: ferric carboxymaltose - ferric carboxymaltose 1000 mg (or similar product) given Intravenously

Placebo Comparator: Placebo - Placebo intravenous infusion


Treatment: drugs: Ferric carboxymaltose
treatment for Iron deficient anaemia

Treatment: drugs: Placebo
placebo - no active drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Days alive and out of hospital. - 30 days post surgery. the number of days the patient was not in hospital or care facility during the 30 day period from surgery.</outcome>
      <timepoint>induction of anaesthesia for cardiac surgery up to 30 days post operatively</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correction of anemia following administration of trial drug to day of surgery measure by hemoglobin - following administration of trial drug to day of surgery. Analysis of the Haemoglobin changes.</outcome>
      <timepoint>from administration of trial drug up to induction of anaesthesia for cardiac surgery up to 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intensive care stay - Total days in hospital and Intensive care from induction of anaesthesia for cardiac surgery up until 30 days post operation</outcome>
      <timepoint>induction of anaesthesia for cardiac surgery to 30 days post operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hospital stay - Total days in hospital from induction of anaesthesia for cardiac surgery up until 30 days post operation</outcome>
      <timepoint>induction of anaesthesia for cardiac surgery to 30 days post operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disability-free survival - Using the WHODAS to measure disability post operatively up to180 days from surgery. disability will be measured as an increased score of =4 for a period of = 3months</outcome>
      <timepoint>180 days from induction of anaesthesia for cardiac surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>90-day survival - mortality within 90 days from induction of anaesthesia for cardiac surgery</outcome>
      <timepoint>induction of anaesthesia for cardiac surgery up to 90 days post operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>units of allogeneic blood transfused - number of blood products transfused</outcome>
      <timepoint>induction of anaesthesia for cardiac surgery to discharge from hospital up to 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life - 180 days from induction of anaesthesia for cardiac surgery</outcome>
      <timepoint>induction of anaesthesia for cardiac surgery up to 180 days post operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost-effectiveness - comparative cost analysis for the use of iron v's placebo</outcome>
      <timepoint>From trial drug administration to 180 days from induction of anaesthesia for cardiac surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients with anaemia (males Hb &lt;130 g/L, females &lt;120 g/L) undergoing elective
             cardiac surgery, and available to receive trial drug 1- 10 weeks prior to surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnancy

          -  Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its
             excipients

          -  Known or suspected haemoglobinopathy/thalassaemia

          -  Bone marrow disease

          -  Haemochromatosis

          -  Renal dialysis

          -  Erythropoietin or IV iron in the previous 4 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Health - Melbourne</hospital>
    <postcode>3181 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomised double-blind, controlled phase IV trial will compare the efficacy, safety and
      cost-effectiveness of preoperative IV iron with placebo in patients with anaemia before
      elective cardiac surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02632760</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul S Myles, MD</name>
      <address>Bayside Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Paul S Myles, MD</name>
      <address />
      <phone>+61390762000</phone>
      <fax />
      <email>p.myles@alfred.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>